ZTE Launches Intelligent Computing Solutions at MWC Barcelona 2024

At the MWC Barcelona 2024, ZTE Corporation unveiled its latest endeavor in intelligent computing solutions. This strategic move is designed to propel digital and intelligent transformation across various sectors, marking a significant milestone in the industry’s evolution towards a more interconnected and smart future.

MWC Barcelona 2024: ZTE’s Full-Stack Computing Infrastructure

ZTE has developed a full-stack computing infrastructure that addresses the increasing need for diverse computing power and high energy efficiency. The infrastructure provides end-to-end solutions that include heterogeneous computing power, high-performance storage, lossless networks, and fully liquid-cooled data centers. The aim is to cater to the requirements of both general and intelligent computing scenarios across various industries.

AiCube All-in-One Cabinet

ZTE’s AiCube is an innovative all-in-one cabinet solution that revolutionizes edge computing. It is a compact and powerful device that integrates AI computing, storage, network, and AI platform software into a single package.

One of the most significant advantages of the AiCube is that it supports mainstream AI frameworks, including TensorFlow, PyTorch, and Caffe. This significantly reduces the training and inference costs for private field AI models. The device also lowers technical barriers for businesses that want to develop and deploy AI models for specific applications. 

AiCube also enhances enterprise data security by keeping sensitive data within the company’s premises. The device has advanced security features that protect against data breaches or cyber-attacks.

IceCube High-Density Full Liquid-Cooled Cabinet

IceCube is a high-density, fully liquid-cooled cabinet set to revolutionize the green data center space. It is the perfect blend of innovation, performance, and sustainability. It is designed to cater to the ever-growing demand for more efficient and eco-friendly data centers.

With the ability to house up to 40 1U servers, the IceCube boasts unparalleled computing density and efficiency. This is achieved through its unique blind mating design and highly efficient liquid cooling cabin doors. These help the data center achieve an impressive pPUE of less than 1.1. This is remarkable compared to traditional data centers. Typically, traditional data centers have a pPUE of around 1.5-2.0.

The IceCube’s design also ensures that the cabinet’s doors remain closed, preventing air leaks. The liquid cooling cabin doors effectively remove heat from the servers and transfer it to the liquid coolant.  

ZTE has created a product that helps reduce carbon emissions and energy consumption. With the IceCube, data center operators can enjoy reduced operating costs, improved energy efficiency, and a reduced environmental footprint.

AI Booster Intelligent Computing Platform

The AI Booster Intelligent Computing Platform is a cutting-edge solution revolutionizing how businesses utilize artificial intelligence. The platform aims to simplify and optimize the use of AI technologies, making them more accessible and efficient.   

The AI Booster platform optimizes GPU utilization for faster and more efficient AI model training. Using automatic parallel training optimizes computational resources, reducing the time and resources required for AI model development. The platform simplifies development and training by incorporating visual development tools and a zero-code design interface. 

Another standout feature of the AI Booster is its self-adaptive parameter optimization. This automates the fine-tuning of AI models. This ensures you achieve the best possible performance with minimal human intervention.

By simplifying the optimization process, ZTE’s platform helps businesses scale their AI solutions and remain competitive.

MWC24: ZTE Generative AI to All Scenarios

ZTE’s innovative approach to integrating Generative AI in various scenarios demonstrates its dedication to improving industry efficiency and leading modernization efforts.

Research and Development

ZTE is transforming the Research and Development sector by introducing a coding assistant application powered by Nebula Encoding’s large model. This advanced tool enhances developers’ capabilities and streamlines the coding processes. Thus, reducing time spent on routine tasks such as debugging.

The outcome is a significant 20% improvement in overall research and development efficiency, which facilitates faster innovation cycles and the rapid development of cutting-edge solutions.

Telecommunications

ZTE, a leader in the telecom industry, has achieved a significant breakthrough by enabling the commercial use of autonomous networks. This was made possible by deploying the Nebula telecommunication large model, marking the industry’s first smart event. The autonomous network uses advanced AI algorithms and can self-optimize, self-healing, and predictive maintenance.

This results in enhanced network reliability, reduced downtime, and improved user service quality. This initiative highlights ZTE’s leadership in telecom innovation and contributes to the evolution of smarter, more efficient telecommunication infrastructure.

Industrial

Implementing the Nebula CV (Computer Vision) model significantly advances Industrial Parks to improve security and operational efficiency. ZTE applies this advanced model to campus-wide security systems, supporting multiple security operation scenarios. This includes surveillance, access control, incident detection, and response.

Adopting the Nebula CV model results in an impressive 35% increase in overall operation efficiency, demonstrating the powerful capabilities of AI in streamlining processes, enhancing safety measures, and ensuring a secure environment for industrial activities.

ZTE is making significant strides at MWC Barcelona 2024 by introducing a comprehensive computing infrastructure that is powered by AI innovations. This marks a significant shift towards enhancing industry efficiency and modernization. By strategically applying generative AI across various sectors, ZTE is not just shaping the future of technology but also empowering industries to embrace a smarter and more efficient tomorrow.

Media Contact
Company Name: ZTE Corporation
Contact Person: Lunitta LU
Email: Send Email
Country: China
Website: https://www.zte.com.cn/global/

Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024

DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024″ report provides comprehensive insights about 20+ Advanced Merkel Cell Carcinoma Companies and 20+ pipeline drugs in the Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

  • DelveInsight’s Advanced Merkel Cell Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
  • The leading companies working in the Advanced Merkel Cell Carcinoma market include Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Promising Advanced Merkel Cell Carcinoma Pipeline Therapies in the various stages of development include Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for vidutolimod and cemiplimab. The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
  • December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.
  • On August 2023, H. Lee Moffitt Cancer Center and Research Institute announced a study of Phase 1 Clinical Trials for Cemiplimab-Rwlc. The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
  • On July 2023, 4SC AG announced a study of Phase 2 Clinical Trials for Domatinostat in Combination with Avelumab. This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody.
  • On June 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase 2 Clinical Trials for Avelumab. This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
  • On February 2023, Merck Sharp & Dohme LLC announced a study of Phase 3 Clinical Trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

 

Request a sample and discover the recent advances in Advanced Merkel Cell Carcinoma Treatment Drugs @ Advanced Merkel Cell Carcinoma Infection Pipeline Report

 

The Advanced Merkel Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Merkel Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Merkel Cell Carcinoma clinical trial landscape.

 

Advanced Merkel Cell Carcinoma Overview

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease.

 

Find out more about Advanced Merkel Cell Carcinoma Treatment Drugs @ Drugs for Advanced Merkel Cell Carcinoma Treatment

 

Advanced Merkel Cell Carcinoma Emerging Drugs Profile

  • Tidutamab: Xencor, Inc.
  • Cabozantinib: Exelixis

 

Advanced Merkel Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The Advanced Merkel Cell Carcinoma companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

 

Learn more about the emerging Advanced Merkel Cell Carcinoma Pipeline Therapies @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Merkel Cell Carcinoma Companies- Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Advanced Merkel Cell Carcinoma Pipeline Therapies- Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.

 

Dive deep into rich insights for new drugs for Advanced Merkel Cell Carcinoma treatment, Visit @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Merkel cell carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Cabozantinib: Exelixis
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. IFx-Hu2.0: Morphogenesis
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Advanced Merkel cell carcinoma Key Companies
  15. Advanced Merkel cell carcinoma Key Products
  16. Advanced Merkel cell carcinoma- Unmet Needs
  17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
  18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
  19. Advanced Merkel cell carcinoma Analyst Views
  20. Advanced Merkel cell carcinoma Key Companies
  21. Appendix

 

For further information on the Advanced Merkel Cell Carcinoma pipeline therapeutics, reach out to Advanced Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024

Anti-CD20 Antibody Pipeline Outlook Report 2024

DelveInsight’s, “Anti-CD20 Antibody Pipeline Insight 2024” report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Anti-CD20 Antibody Pipeline Report

  • DelveInsight’s Anti-CD20 Antibody pipeline report depicts a robust space with 20+ Anti-CD20 Antibody companies working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.
  • The leading companies working in the Anti-CD20 Antibody market include TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
  • On July 2023, University of Washington announced a study of Phase 2 Clinical Trials for Obinutuzumab, Rituximab, and Pembrolizumab. This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory).
  • On July 2023, Cho Pharma Inc. announced a study of Phase 1 & 2 Clinical Trials for CHO-H01. This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin’s lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
  • On August 2023, BeiGene announced a study of Phase 3 Clinical Trials for Zanubrutinib, Rituximab, Lenalidomide, and Obinutuzumab. The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

 

Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @ Anti-CD20 Antibody Pipeline Report

 

The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.

 

Anti-CD20 Antibody Overview

CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells.

 

Find out more about Anti-CD20 Antibody Treatment Landscape @ Drugs for Anti-CD20 Antibody Treatment

 

Anti-CD20 Antibody Emerging Drugs Profile

  • Ublituximab: TG therapeutics
  • Glofitamab: Roche

 

Anti-CD20 Antibody Pipeline Therapeutics Assessment

The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @ Anti-CD20 Antibody Clinical Trials Assessment

 

Scope of the Anti-CD20 Antibody Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Anti-CD20 Antibody Companies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Anti-CD20 Antibody Pipeline Therapies- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.

 

Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @ Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anti-CD20 Antibody: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anti-CD20 Antibody – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anti-CD20 Antibody Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Ublituximab: TG therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Odronextamab: Regeneron Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. IGM 2323: IGM Biosciences
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Anti-CD20 Antibody Key Companies
  20. Anti-CD20 Antibody Key Products
  21. Anti-CD20 Antibody- Unmet Needs
  22. Anti-CD20 Antibody- Market Drivers and Barriers
  23. Anti-CD20 Antibody- Future Perspectives and Conclusion
  24. Anti-CD20 Antibody Analyst Views
  25. Anti-CD20 Antibody Key Companies
  26. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD20 Antibody Pipeline Outlook Report 2024

Primary Hyperoxaluria Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Primary Hyperoxaluria Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

 

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years. 
  • Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment 
  • Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.   
  • In September 2022, Novo Nordisk has presented Nedosiran to the FDA in the United States for regulatory consideration.
  • In February 2022, Dicerna Pharmaceuticals, Inc. has commenced a Phase II open-label multicenter investigation to assess the safety, pharmacokinetics, and effectiveness of Nedosiran in pediatric patients ranging from birth to 11 years old, specifically those diagnosed with primary hyperoxaluria and possessing relatively preserved renal function.

 

Primary Hyperoxaluria Overview

Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that is normally eliminated through the kidneys in the urine. In individuals with Primary Hyperoxaluria, there is a defect in the liver enzymes responsible for breaking down glyoxylate, leading to an accumulation of oxalate in the body.

 

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

 

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

  • CHK-336: Chinook Therapeutics
  • BBP-711: Cantero Therapeutics
  • BMN 255: BioMarin Pharmaceutical, Inc
  • Oxabact: OxThera
  • Nedosiran: Dicerna Pharmaceuticals, Inc.

 

Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Primary Hyperoxaluria Pipeline Therapeutics Assessment

  • Primary Hyperoxaluria Assessment by Product Type
  • Primary Hyperoxaluria By Stage and Product Type
  • Primary Hyperoxaluria Assessment by Route of Administration
  • Primary Hyperoxaluria By Stage and Route of Administration
  • Primary Hyperoxaluria Assessment by Molecule Type
  • Primary Hyperoxaluria by Stage and Molecule Type

 

DelveInsight’s Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies

 

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are – Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.

 

Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
  • Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Primary Hyperoxaluria Pipeline Market Drivers

  • Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Primary Hyperoxaluria Market.

 

Primary Hyperoxaluria Pipeline Market Barriers

  • However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

 

Scope of Primary Hyperoxaluria Pipeline Drug Insight    

  • Coverage: Global
  • Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
  • Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
  • Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
  • Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 

 

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials

 

Table of Contents

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Hyperoxaluria Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer

COVID-19 Competitive Landscape 2023 (Updated)

DelveInsight’s, “COVID-19 Competitive Landscape 2023” report provides comprehensive insights about 400+ COVID-19 Companies and 500+ drugs in Covid-19 Competitive landscape. It covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the COVID-19 Report

  • DelveInsight’s COVID-19 report depicts a robust space with 400+ active players working to develop 500+ pipeline therapies for COVID-19 treatment.
  • The leading companies working in the COVID-19 Market include Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
  • Promising COVID-19 therapies in the various stages of development includes XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
  • November 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD7442. This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
  • November 2023: BioNTech SE announced a study of Phase 1 clinical trials for BNT162b4 5 µg. The trial will use a staggered dosing process schema, i.e., enrollment into the next higher dose level is done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as Cohort 3a but in participants aged >55 years will be opened after safety data for participants aged 18-55 years in Cohort 3a has been reviewed.

 

Request a sample and discover the recent advances in COVID-19 Drugs @ COVID-19 Competitive Landscape Report

 

The COVID-19 report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the COVID-19 report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

COVID-19 Overview

Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans several known coronaviruses cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

 

Find out more about COVID-19 Analytical Perspective: In-depth Commercial Assessment @ COVID-19 Collaboration Analysis by Companies

 

COVID-19 Companies and Therapies

  • Nobelpharma: Sargramostim
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd: BDB-001
  • NeuroActiva Inc.: NA-831
  • Nanogen Pharmaceutical Biotechnology: Nanocovax

 

COVID-19 Competitive Landscape

The COVID-19 report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

COVID-19 Report Assessment

  • Company Analysis
  • COVID-19 Therapeutic Assessment
  • COVID-19 Pipeline Assessment
  • Inactive drugs assessment
  • COVID-19 Unmet Needs

 

Learn more about the emerging COVID-19 Competitive Landscape @ COVID-19 Market Drivers and Barriers, Unmet Needs

 

Scope of the COVID-19 Report

  • Coverage- Global
  • COVID-19 Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • COVID-19 Companies- Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
  • COVID-19 therapies- XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.

  

Dive deep into rich insights for new drugs for COVID-19 Product Developmental Activities, Visit @ COVID-19 Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. COVID-19: Overview
  4. COVID-19 -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. COVID-19: Company and Product Profiles (Marketed Therapies)
  8. AstraZeneca
  9. AZD1222
  10. COVID-19: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Vicore Pharma
  13. C21
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Company Name
  17. Product Name
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. Enanta Pharmaceuticals
  21. EDP 235
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. COVID-19- Unmet needs
  29. COVID-19 – Market drivers and barriers
  30. Appendix

 

For further information on the COVID-19 Report @ COVID-19 Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COVID-19 Competitive Landscape 2023 (Updated)

Thyroid Cancer Pipeline Insights Report 2024

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 40+ Thyroid Cancer companies and 40+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Thyroid Cancer Pipeline Report

  • DelveInsight’s Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
  • The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Trametinib and Dabrafenib. This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
  • November 2023: Affylmmune Therapeutics Inc. announced a study of Phase 1 clinical trials for AIC100 CAR T Cells. The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
  • In July 2023, Eisai Limited announced a study of phase 1 & 2 clinical trials for Lenvatinib, Ifosfamide, and Etoposide. This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).
  • On January 2023, Famewave Ltd announced a study of phase 1 & 2 clinical trials for Nivolumab and Nal-IRI/5-FU/LV – Expansion. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

 

Request a sample and discover the recent advances in Thyroid Cancer Treatment Drugs @ Thyroid Cancer Pipeline Outlook Report

 

In the Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Thyroid Cancer Overview

Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one.

 

Find out more about Thyroid Cancer Therapeutics Assessment @ Thyroid Cancer Preclinical and Discovery Stage Products

 

Thyroid Cancer Emerging Drugs Profile

  • Donafenib: Suzhou Zelgen Biopharmaceuticals
  • Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Nivolumab: Bristol-Myers Squibb
  • RX208: Suzhou NeuPharma
  • AIC100: AffyImmune Therapeutics

 

Thyroid Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Thyroid Cancer therapies. The Thyroid Cancer companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

 

Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation

 

Thyroid Cancer Drugs and Companies

  • Rosiglitazone: Exelixis
  • Lenvatinib: Eisai Limited
  • Ifosfamide: Merck Sharp & Dohme LLC

 

Thyroid Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Thyroid Cancer Therapeutics Market include-

Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.

 

Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views

 

Scope of the Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Thyroid Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Donafenib: Suzhou Zelgen Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nivolumab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100: Affyimmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Thyroid Cancer Key Companies
  21. Thyroid Cancer Key Products
  22. Thyroid Cancer- Unmet Needs
  23. Thyroid Cancer- Market Drivers and Barriers
  24. Thyroid Cancer- Future Perspectives and Conclusion
  25. Thyroid Cancer Analyst Views
  26. Thyroid Cancer Key Companies
  27. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Cancer Pipeline Insights Report 2024

360Wise Media and McDonald’s Celebrate Success of “Faces of Black History” Campaign with Over 2 Million Event Visits

360Wise Media and McDonald's Celebrate Success of "Faces of Black History" Campaign with Over 2 Million Event Visits

“We are thrilled by the incredible response to the ‘Faces of Black History’ campaign,” said Robert Alexander, CEO of 360Wise Media. “This campaign was a labor of love, and we are grateful to McDonald’s for their partnership and support. Together, we were able to create a meaningful and impactful experience that resonated with millions of people across the country.”
In a groundbreaking partnership, 360Wise Media and McDonald’s are thrilled to announce the outstanding success of the “Faces of Black History” campaign. This innovative campaign, designed to honor and celebrate the contributions of African Americans to culture, history, and society, has garnered over 2 million event visits nationwide.

360Wise Media, in partnership with McDonald’s, is proud to announce the overwhelming success of the “Faces of Black History” campaign, which attracted over 2 million event visits nationwide, as confirmed by Google Analytics GA4.

The “Faces of Black History” campaign was launched to honor and celebrate the contributions of Black Americans to culture, history, and society. Through a series of engaging events and initiatives, the campaign highlighted the achievements of Black leaders, artists, activists, and entrepreneurs, inspiring audiences to learn, reflect, and take action.

“We are thrilled by the incredible response to the ‘Faces of Black History’ campaign,” said Robert Alexander, CEO of 360Wise Media. “This campaign was a labor of love, and we are grateful to McDonald’s for their partnership and support. Together, we were able to create a meaningful and impactful experience that resonated with millions of people across the country.”

The success of the “Faces of Black History” campaign is a testament to the power of storytelling and community engagement. By sharing stories of resilience, triumph, and achievement, the campaign sparked conversations, fostered connections, and inspired individuals to celebrate Black history not just during Black History Month, but every day of the year.

“We are incredibly proud of the impact that the ‘Faces of Black History’ campaign has had on our communities,” said, McDonald’s Faces of Black History Tour Manager Terry Gadson, Chief Operating Oficer at Irving Street Rep. “At McDonald’s, we believe in the importance of celebrating diversity and inclusion, and this campaign allowed us to do just that. We look forward to continuing our partnership with 360Wise Media and creating more meaningful experiences for our customers.”

As the “Faces of Black History” campaign comes to a close, 360Wise Media and McDonald’s are already looking ahead to future collaborations. Together, they remain committed to celebrating diversity, promoting inclusion, and honoring the rich tapestry of Black history and culture.

 

Media Contact
Company Name: 360Wise Media
Contact Person: Robert Alexander
Email: Send Email
Phone: 1-844-360-9473
Address:1200 Brickell Ave suite 1950
City: Miami
State: Florida
Country: United States
Website: https://360Wise.com

Bispecific Antibody Competitive Landscape Report 2023

DelveInsight’s, “Bispecific antibody Competitive landscape, 2023,” report provides comprehensive insights about 250+ Bispecific Antibody companies and 300+ Bispecific Antibody drugs in Bispecific antibody Competitive landscape. It covers the Bispecific Antibody therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Bispecific Antibody Competitive Landscape Report

  • DelveInsight’s Bispecific Antibody report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Bispecific Antibody treatment.
  • The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
  • Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
  • December 2023: Hoffmann-La Roche, An Open Label, Multicenter, Dose Escalation, Phase 1 & 2 Clinical Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors.
  • December 2023: Janssen Research & Development Inc. announced a study of Phase 1 clinical trials for Teclistamab (IV). The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

 

Request a sample and discover the recent advances in Bispecific Antibody Drugs @ Bispecific Antibody Competitive Landscape Report

 

The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition – deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

Bispecific Antibody Overview

Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146–160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.

 

Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies

 

Bispecific Antibody Companies and Product Profile

  • Akeso: Ivonescimab
  • Zymeworks: Zanidatamab
  • Roche: Glofitamab
  • IGM Biosciences: Imvotamab
  • MacroGenics: MGD024

 

Bispecific Antibody Competitive Landscape

The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Bispecific Antibody Report Assessment

  • Bispecific Antibody Company Analysis
  • Bispecific Antibody Therapeutic Assessment
  • Bispecific Antibody Pipeline Assessment
  • Inactive drugs assessment
  • Bispecific Antibody Unmet Needs

 

Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs

 

Scope of the Bispecific Antibody Report

  • Coverage- Global
  • Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
  • Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.

 

Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bispecific antibody: Overview
  4. Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. Bispecific antibody: Company and Product Profiles (Marketed Therapies)
  8. Janssen
  9. Amivantamab
  10. Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Akeso
  13. Ivonescimab
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. IGM Biosciences
  17. Imvotamab
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. MacroGenics
  21. MGD024
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. Bispecific antibody- Unmet needs
  29. Bispecific antibody – Market drivers and barriers
  30. Appendix

 

For further information on the Bispecific Antibody Report @ Bispecific Antibody Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bispecific Antibody Competitive Landscape Report 2023

Gene therapy Competitive Landscape Report 2023 (Updated)

DelveInsight’s, “Gene Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ Gene Therapy companies and 300+ Gene Therapy drugs in the Gene therapy Competitive landscape. It covers the Gene Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gene Therapy Competitive Landscape Report

  • DelveInsight’s Gene Therapy report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Gene Therapy treatment.
  • The leading companies working in the Gene Therapy Market include Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
  • Promising Gene Therapy Therapies in the various stages of development include ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.
  • December 2023Sangamo Therapeutics announced a study of Phase 1 & 2 clinical trials for ST-920. This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3.
  • December 2023: Regenxbio Inc. announced a study of Phase 1 & 2 clinical trials for RGX-202. RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.

 

Request a sample and discover the recent advances in Gene Therapy @ Gene Therapy Competitive Landscape Report

 

The Gene Therapy report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Gene Therapy report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Gene Therapy Overview

Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, gene therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophiliaand sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with gene therapy.

 

Find out more about Gene Therapy Analytical Perspective: In-depth Commercial Assessment @ Gene Therapy Collaboration Analysis by Companies

 

Gene Therapy Companies and Therapies

  • Candel Therapeutics: CAN-2409
  • CRISPR Therapeutics: CTX001
  • TILT Biotherapeutics: TILT-123
  • Akamis Bio: NG-347

 

Gene Therapy Competitive Landscape

The Gene Therapy report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Gene Therapy Pipeline Report Assessment

  • Gene Therapy Company Analysis
  • Gene Therapy Therapeutic Assessment
  • Gene Therapy Pipeline Assessment
  • Gene Therapy Inactive drugs assessment
  • Gene Therapy Unmet Needs

 

Learn more about the emerging Gene Therapy Competitive Landscape @ Gene Therapy Market Drivers and Barriers, Unmet Needs

 

Scope of the Gene Therapy Report

  • Coverage- Global
  • Gene Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • Gene Therapy Companies- Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
  • Gene Therapy Therapies- ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.

 

Dive deep into rich insights for new drugs for Gene Therapy Product Developmental Activities, Visit @ Gene Therapy Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gene Therapy: Overview
  4. Gene Therapy -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. Gene Therapy: Company and Product Profiles (Marketed Therapies)
  8. Juno Therapeutics, Inc./Bristol-Myers Squibb
  9. BREYANZI
  10. Gene Therapy: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Candel Therapeutics
  13. CAN-2409
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Company Name
  17. Product Name
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. TILT Biotherapeutics
  21. TILT-123
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. Gene Therapy- Unmet needs
  29. Gene Therapy – Market drivers and barriers
  30. Appendix

 

For further information on the Gene Therapy Report @ Gene Therapy Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene therapy Competitive Landscape Report 2023 (Updated)

CAR-T Cell Therapy Competitive Landscape 2023 (Updated)

DelveInsight’s, “CAR T Cell Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ CAR-T Cell Therapy companies and 500+ drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Cell Therapy Report

  • DelveInsight’s CAR-T Cell Therapy report depicts a robust space with 250+ active players working to develop 500+ pipeline therapies for CAR-T Cell Therapy treatment.
  • The leading companies working in the CAR-T Cell Therapy Market include Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
  • Promising CAR-T Cell Therapy Therapies in the various stages of development include Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.
  • December 2023: Peter MacCallum Cancer Centre, Australia announced a study of phase 1 clinical trials for JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent. This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI).
  • December 2023: University of Pennsylvania announced a study of Phase 2 clinical trials for Cevostamab. This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed CAR T cell therapy may be identified pre-CAR T cell infusion but are not consented and enrolled until at least 4-6 weeks after CAR T cell infusion, once recovered from acute toxicities.

 

Request a sample and discover the recent advances in CAR-T Cell Therapy Drugs @ CAR-T Cell Therapy Competitive Landscape Report

 

The CAR-T Cell Therapy report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition – deal values trends. The sub-segmentation is described in the CAR-T Cell Therapy report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

CAR-T Cell Therapy Overview

CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signaling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.

 

Find out more about CAR-T Cell Therapy Analytical Perspective: In-depth Commercial Assessment @ CAR-T Cell Therapy Collaboration Analysis by Companies

 

CAR-T Cell Therapy Companies and Therapies

  • CARsgen: Zevorcabtagene autoleucel
  • Cartesian Therapeutics: Descartes 011
  • Autolus Therapeutics PLC: AUTO8
  • Sana Biotechnology: SG299

 

CAR T- Cell Therapy Competitive Landscape

The CAR-T Cell Therapy competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

CAR T- Cell Therapy Report Assessment

  • CAR T-Cell Therapy Company Analysis
  • CAR T-Cell Therapy Therapeutic Assessment
  • CAR T- Cell Therapy Pipeline Assessment
  • CAR T-Cell Therapy Inactive Drugs Assessment
  • CAR T-Cell Therapy Unmet Needs

 

Learn more about the emerging CAR-T Cell Therapy Competitive Landscape @ CAR-T Cell Therapy Market Drivers and Barriers, Unmet Needs

 

Scope of the CAR-T Cell Therapy Report

  • Coverage- Global
  • CAR-T Cell Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • CAR-T Cell Therapy Companies- Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
  • CAR-T Cell Therapy Therapies- Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.

 

Dive deep into rich insights for new drugs for CAR-T Cell Therapy Product Developmental Activities, Visit @ CAR-T Cell Therapy Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. CAR T – Cell Therapy: Overview
  4. CAR T – Cell Therapy-Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. CAR T – Cell Therapy: Company and Product Profiles (Marketed Therapies)
  8. JW Therapeutics
  9. Relmacabtagene autoleucel
  10. Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Registered)
  12. CARsgen
  13. Zevorcabtagene autoleucel
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Cartesian Therapeutics
  17. Descartes 011
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. Autolus Therapeutics
  21. AUTO-8
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Sana Biotechnology
  25. SG299
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. CAR T – Cell Therapy – Unmet needs
  29. CAR T – Cell Therapy– Market drivers and barriers
  30. Appendix

 

For further information on the CAR-T Cell Therapy Report @ CAR-T Cell Therapy Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Cell Therapy Competitive Landscape 2023 (Updated)